InSights Videos
PharmaVentures InSights: The impact of conference cancellations on dealmaking during the Covid-19 pandemic
Can Partnering Conference Cancellations Affect Dealmaking in 2020? We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we...
Doing deals in the healthcare sector during the Covid-19 pandemic.
The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals. https://youtu.be/o81Th7McuHA
Key Questions When Doing a Deal with Big Pharma: A Conversation with PharmaVentures (한국어 버전)
What are the most important things to think about when doing a licensing deal with Western big pharma? How do you engage with them and keep the momentum going? Can language become a barrier in doing a deal? How is the Korean biopharmaceutical sector viewed by those of...
Why you should make South Korea a deal making target
Over the past couple of years, we have seen huge growth in the pharma and biotech industries in Asia, and especially in Korea. Historically, the Korean pharmaceutical industry was built on manufacturing and generics capabilities, however, in the past few decades many...
Video Interview: NetScientific, Fighting chronic diseases on three fronts.
With more than 89 million chronic disease sufferers in the US alone, NetScienctific is focused on fighting chronic diseases on three fronts to create 'next generation healthcare technologies'. Thier healthcare investment strategy is building businesses in digital...
Featured Videos
Please see PharmaVentures Insights YouTube channel for more videos
Blog Articles
PharmaVentures’ Industry Insight: We predict that licensing and partnering activity will remain steady in 2020
As we all know deal making is the life and blood of the biopharma industry and today this activity...
Are you Planning to Divest R&D or Manufacturing Facilities?
To download the full article please click here
PharmaVentures are Media Partners at the World Stem Cells & Regenerative Medicine Congress 2015
PharmaVentures and PharmaTelevision are delighted to be Media Partners at the World Stem...
Season’s Greetings from PharmaVentures 2014
Convergence of Healthcare with ICT accelerates
By Ping ShekThe healthcare market today is driven by the overriding need to deliver better patient...
Pfizer/AZ: The bigger issue is not M&A but how in the future we find effective medicines
The debate and discussions in the media on the attempted bid by Pfizer for AstraZeneca (AZ)...
Pfizer+AZ: Will Mega-Merger Mania Return?
Today the talking point, of course, is the bid by Pfizer for AstraZeneca (AZ) and whether...
Pharma is attracted to early-stage antibody deals in Oncology
Today, the top ten best-selling antibody therapeutics for cancer have accumulated revenues...
Can 2014 be better than 2013?
I predict that 2014 will be a year where the pharmaceutical industry will be stronger,...
Season’s Greetings from PharmaVentures
Biotech Bounces Back
On the 31st July of this year the Financial Times front page headline to its Companies and Markets...
White Papers

Deal Making in the Year of Covid-19
In the Spring of 2020, during the early days of the COVID-19 pandemic when there were real fears of a global downturn, PharmaVentures predicted that despite the forthcoming challenges, licensing and partnering would remain steady during 2020. With the year behind us,...
Our News

PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor
Oxford, UK, 24th November 2020 PharmaVentures today announced it has acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4. GPCR has signed an exclusive agreement with TaiGen Biotechnology...